Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie som sammenligner teclistamab monoterapi versus pomalidomid, bortezomib, deksametason (PVd) eller karfilzomib, deksametason (Kd) hos deltakere med residiverende eller refraktært myelomatose (MajesTEC-9)

2. november 2026 oppdatert av: Janssen Research & Development, LLC

En randomisert fase 3-studie som sammenligner teclistamab monoterapi versus pomalidomid, bortezomib, deksametason (PVd) eller karfilzomib, deksametason (Kd) hos deltakere med residiverende eller refraktært myelomatose som har mottatt 1 til 3 tidligere antikroppslinjer av Monrapylon og CD-38 og Lenalidomid

The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

614

Fase

  • Fase 3

Utvidet tilgang

Godkjent for salg til publikum. Se utvidet tilgangspost.

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Blacktown, Australia, 2148
        • Blacktown Hospital
      • Fitzroy, Australia, 3065
        • St Vincents Hospital Melbourne
      • Melbourne, Australia, 3128
        • Box Hill Hospital
      • Murdoch, Australia, 6150
        • Fiona Stanley Hospital
      • Nedlands, Australia, 6009
        • Sir Charles Gairdner Hospital
      • Brasschaat, Belgia, 2930
        • Algemeen Ziekenhuis Klina
      • Haine-St-Paul, Belgia, 7100
        • Jolimont
      • Kortrijk, Belgia, 8500
        • Az Groeninge
      • Leuven, Belgia, 3000
        • Universitair Ziekenhuis Gasthuisberg
      • Liège, Belgia, 4000
        • CHR de la Citadelle
      • Brasília, Brasil, 70390-140
        • Hospitais Integradaos da Gavea S/A - DF Star
      • Caxias do Sul, Brasil, 95070 560
        • Fundacao Universidade de Caxias do Sul
      • Curitiba, Brasil, 81520-060
        • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
      • Joinville, Brasil, 89201-260
        • Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
      • Natal, Brasil, 59062 000
        • Liga Norte Riograndense Contra O Cancer
      • Niterói, Brasil, 24020-073
        • Complexo Hospitalar de Niteroi
      • Rio de Janeiro, Brasil, 22775-001
        • Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
      • Salvador, Brasil, 41253-190
        • IDOR - Regional Bahia
      • São José do Rio Preto, Brasil, 15090-000
        • Funfarme Sjrp
      • São Paulo, Brasil, 05652-900
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brasil, 01323-001
        • Hospital Alemao Oswaldo Cruz
      • São Paulo, Brasil, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, Brasil, 01308-901
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
      • São Paulo, Brasil, 04537 081
        • Clinica Medica Sao Germano LTDA
      • São Paulo, Brasil, 01401 002
        • IDOR - Regional Sao Paulo
      • São Paulo, Brasil, 01321-001
        • Real e Benemérita Associação Portuguesa de Beneficência
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Arthur J E Child Comprehensive Cancer Centre
    • New Brunswick
      • Saint John, New Brunswick, Canada, E2L 4L2
        • Saint John Regional Hospital
    • Ontario
      • Brampton, Ontario, Canada, L6R 3J7
        • Brampton Civic Hospital
      • Oshawa, Ontario, Canada, L1G2B9
        • Lakeridge Health Oshawa
    • Quebec
      • Montreal, Quebec, Canada, H1T 2M4
        • CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont
      • Aalborg, Danmark, 9000
        • Aalborg University Hospital
      • Aarhus, Danmark, 8200
        • Aarhus University Hospital
      • Copenhagen, Danmark, DK-2100
        • Rigshospitalet
      • Herning, Danmark, 7400
        • Regionshospitalet Godstrup
      • Odense C, Danmark, 5000
        • Odense Universitetshospital
      • Vejle, Danmark, 7100
        • Vejle Sygehus
    • Alaska
      • Anchorage, Alaska, Forente stater, 99508
        • Alaska Oncology and Hematology LLC
    • Arizona
      • Gilbert, Arizona, Forente stater, 85234
        • Banner MD Anderson Cancer Center
    • California
      • Berkeley, California, Forente stater, 94704
        • Alta Bates Comprehensive Cancer Center
      • Long Beach, California, Forente stater, 90806
        • MemorialCare Long Beach Medical Center
      • Orange, California, Forente stater, 92868
        • University of California Irvine
      • Whittier, California, Forente stater, 90602
        • PIH Health Hospital
    • Colorado
      • Aurora, Colorado, Forente stater, 80218
        • Rocky Mountain Cancer Centers
    • Connecticut
      • Farmington, Connecticut, Forente stater, 06030
        • University of Connecticut
    • Florida
      • Miami, Florida, Forente stater, 33136
        • University of Miami Sylvester Cancer Center
      • Orlando, Florida, Forente stater, 32806
        • Orlando Health Cancer Institute
      • Weston, Florida, Forente stater, 33331
        • Cleveland Clinic Florida
    • Iowa
      • Waukee, Iowa, Forente stater, 50263
        • Mission Cancer Blood
    • Louisiana
      • Metairie, Louisiana, Forente stater, 70006
        • East Jefferson General Hospital Bone Marrow Transport Clinic
    • Maryland
      • Bethesda, Maryland, Forente stater, 20889
        • Walter Reed National Military Medical Center
      • Silver Spring, Maryland, Forente stater, 20904
        • Maryland Oncology Hematology P A
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02118
        • Boston University Medical Center
    • Missouri
      • Chesterfield, Missouri, Forente stater, 63017
        • Saint Lukes Hospital Saint Lukes Cancer Specialists
    • New Jersey
      • Camden, New Jersey, Forente stater, 08103
        • Cooper Health System MD Anderson Cancer Center at Cooper
    • New York
      • New York, New York, Forente stater, 10032
        • Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705
        • Durham VAMC
    • Pennsylvania
      • Lancaster, Pennsylvania, Forente stater, 17601
        • Penn Medicine Lancaster General Health
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37203
        • Tennessee Oncology
    • Texas
      • Fort Sam Houston, Texas, Forente stater, 78234
        • Brooke Army Medical Center
      • Houston, Texas, Forente stater, 77030
        • Baylor College of Medicine
      • Houston, Texas, Forente stater, 77030
        • Michael E DeBakey VA Medical Center
      • Houston, Texas, Forente stater, 77054
        • Harris Health Smith Clinic
    • Utah
      • Salt Lake City, Utah, Forente stater, 84106
        • Utah Cancer Specialists
    • Virginia
      • Fort Belvoir, Virginia, Forente stater, 22060
        • Alexander T. Augusta Military Medical Center
      • Norfolk, Virginia, Forente stater, 23502
        • Virginia Oncology Associates
    • Washington
      • Tacoma, Washington, Forente stater, 98405
        • NorthWest Medical Specialties, PLLC
      • Amiens, Frankrike, 80000
        • CHU Amiens - Hopital Sud
      • Caen, Frankrike, 14000
        • Hôpital Côte de Nacre
      • Grenoble, Frankrike, 38700
        • CHU Grenoble
      • Le Mans, Frankrike, 72037
        • Centre Hospitalier du Mans
      • Lille, Frankrike, 59020
        • Hopital Saint Vincent de Paul
      • Montpellier, Frankrike, 34295 cede
        • CHU de Montpellier Hopital Saint Eloi
      • Nantes, Frankrike, 44000
        • CHU Nantes
      • Paris, Frankrike, 75743
        • Hopital Necker Enfants Malades
      • Paris, Frankrike, 75012
        • Hopital Saint-Antoine
      • Paris, Frankrike, 75013
        • Hopital de la Pitie Salpetriere
      • Toulouse, Frankrike, 31100
        • Institut Universitaire du Cancer Toulouse Oncopole
      • Vandœuvre-lès-Nancy, Frankrike, 54500
        • CHU de Nancy - Hopital de Brabois
      • Athens Attica, Hellas, 115 28
        • Alexandra General Hospital of Athens
      • Pátrai, Hellas, 263 35
        • Agios Andreas General Hospital of Patra
      • Thessaloniki, Hellas, 570 10
        • G Papanikolaou Hospital of Thessaloniki
      • Gūrgaon, India, 122002
        • Fortis Memorial Research Institute
      • Jaipur, India, 302017
        • Bhagwan Mahaveer Cancer Hospital & Research Centre
      • Pune, India, 411004
        • Deenanath Mangeshkar Hospital and Research Centre
      • Hadera, Israel, 3810101
        • Hillel Yaffe Medical Center
      • Haifa, Israel, 31048
        • Bnai Zion Medical Center
      • Haifa, Israel, 3436212
        • Carmel Medical Center
      • Petah Tikva, Israel, 49100
        • Rabin Medical Center
      • Ramat Gan, Israel, 52621
        • Sheba Medical Center
      • Tel Aviv, Israel, 64239
        • Tel Aviv Sourasky Medical Center
      • Bologna, Italia, 40138
        • A O U Sant Orsola Malpighi
      • Milan, Italia, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Palermo, Italia, 90127
        • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
      • Pisa, Italia, 56126
        • Ospedale Santa Chiara AO Universitaria Pisana
      • Reggio Emilia, Italia, 42123
        • Arcispedale Santa Maria Nuova - IRCCS
      • Roma, Italia, 00128
        • Campus Bio Medico di Roma
      • Siena, Italia, 53100
        • A O Universitaria Senese Ospedale Santa Maria alle Scotte
      • Turin, Italia, 10126
        • A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
      • Udine, Italia, 33100
        • ASUI Santa Maria della Misericordia di Udine
      • Varese, Italia, 21100
        • Ospedale di Circolo e Fondazione Macchi
      • Bunkyō City, Japan, 113 8519
        • Institute of Science Tokyo Hospital
      • Chiba, Japan, 260-8717
        • Chiba Cancer Center
      • Gifu, Japan, 503-8502
        • Ogaki Municipal Hospital
      • Gunma, Japan, 377-0280
        • National Hospital Organization Shibukawa Medical Center
      • Hirakata, Japan, 573 1191
        • Kansai Medical University Hospital
      • Hitachi, Japan, 317-0077
        • Hitachi General Hospital
      • Iruma-gun, Japan, 350-0495
        • Saitama Medical University Hospital
      • Kamogawa, Japan, 296-8602
        • Kameda Medical Center
      • Kashiwa, Japan, 277 8577
        • National Cancer Center Hospital East
      • Kurashiki, Japan, 710-8602
        • Kurashiki Central Hospital
      • Matsuyama, Japan, 790-8524
        • Matsuyama Red Cross Hospital
      • Nagakute, Japan, 480-1195
        • Aichi Medical University Hospital
      • Nagasaki, Japan, 852-8511
        • JRC Nagasaki Genbaku Hospital
      • Niigata, Japan, 951 8520
        • Niigata University Medical And Dental Hospital
      • Okayama, Japan, 701-1192
        • National Hospital Organization Okayama Medical Center
      • Osaka, Japan, 545 8586
        • Osaka Metropolitan University Hospital
      • Sapporo, Japan, 060-8648
        • Hokkaido University Hospital
      • Tokyo, Japan, 113-0033
        • Juntendo University Hospital
      • Tokyo, Japan, 135 8550
        • The Cancer Institute Hospital of JFCR
      • Yamagata, Japan, 990 2331
        • Yamagata University Hospital
      • Yamanashi, Japan, 400-8506
        • Yamanashi Prefectural Central Hospital
      • Beijing, Kina, 100020
        • Beijing Chaoyang Hospital
      • Beijing, Kina, 102208
        • BeiJing JiShuiTan Hospital
      • Changchun, Kina, 130021
        • The First Bethune Hospital of Jilin University
      • Changsha, Kina, 410013
        • The Third Xiangya Hospital, Central South University
      • Chengdu, Kina, 610032
        • Sichuan Provincial Peoples Hospital
      • Chongqing, Kina, 400030
        • Chongqing University Cancer Hospital
      • Fuzhou, Kina, 350001
        • Fujian Meidical University Union Hospital
      • Guangzhou, Kina, 511363
        • Sun Yat -Sen University Cancer Center
      • Hangzhou, Kina, 310003
        • First affiliated Hospital of Zhejiang University
      • Hangzhou, Kina, 310003
        • First affiliated Hospital of Zhejiang University 1
      • Harbin, Kina, 150000
        • Harbin medical university cancer hospital
      • Nanchang, Kina, 330006
        • The First Affiliated Hospital of NanChang University
      • Nanjing, Kina, 210008
        • Nanjing Drum Tower Hospital
      • Nanning, Kina, 530021
        • First Affiliated Hospital of Guangxi Medical University
      • Shanghai, Kina, 200434
        • Shanghai Fourth People s Hospital
      • Shenyang, Kina, 110055
        • Shengjing Hospital Of China Medical University
      • Shenzhen, Kina, 518025
        • Shenzhen 2nd People's Hospital
      • Tianjin, Kina, 300060
        • Tianjin Medical University Cancer Institute and Hospital
      • Tianjin, Kina, 301617
        • Institute of Hematology and Blood Diseases Hospital
      • Wenzhou, Kina, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, Kina, 430023
        • Wuhan Union Hospital
      • Wuxi, Kina, 214023
        • Wuxi People s Hospital
      • Xi'an, Kina, 710004
        • The Second Affiliated Hospital of Xi'an Jiaotong University
      • Zhengzhou, Kina, 450008
        • Henan Cancer Hospital
      • George Town, Malaysia, 10450
        • Hospital Pulau Pinang
      • Kota Kinabalu, Malaysia, 88200
        • Hospital Queen Elizabeth
      • Kuala Lumpur, Malaysia, 59100
        • University Malaya Medical Centre
      • Subang Jaya, Malaysia, 47500
        • Subang Jaya Medical Centre
      • Amersfoort, Nederland, 3813 TZ
        • Meander Medisch Centrum
      • Amsterdam, Nederland, 1081 HV
        • VUMC Amsterdam
      • Groningen, Nederland, 9700 RB
        • Universitair Medisch Centrum Groningen
      • Utrecht, Nederland, 3584 CX
        • UMC Utrecht
      • Gdansk, Polen, 80 214
        • Uniwersyteckie Centrum Kliniczne
      • Katowice, Polen, 40 519
        • Pratia Onkologia Katowice
      • Kielce, Polen, 25 734
        • Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
      • Lublin, Polen, 20-081
        • Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie
      • Almada, Portugal, 2805-267
        • Uls Almada Seixal - Hosp. Garcia de Orta
      • Braga, Portugal, 4710-243
        • Uls Braga - Hosp. Braga
      • Lisbon, Portugal, 1400-038
        • Champalimaud Foundation Champalimaud Centre
      • Porto, Portugal, 4200072
        • Instituto Portugues de Oncologia
      • Vila Nova de Gaia, Portugal, 4434-502
        • Uls Gaia Espinho
      • Badalona, Spania, 08916
        • Hosp. Univ. Germans Trias I Pujol
      • Jerez de la Frontera, Spania, 11407
        • Hosp. de Jerez de La Frontera
      • L'Hospitalet de Llobregat, Spania, 08908
        • Institut Catala d Oncologia L Hospitalet
      • León, Spania, 24008
        • Hosp. de Leon
      • Madrid, Spania, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Spania, 28034
        • Hosp. Univ. Ramon Y Cajal
      • Madrid, Spania, 28031
        • Hosp. Univ. Infanta Leonor
      • Murcia, Spania, 30008
        • Hosp. Gral. Univ. J.M. Morales Meseguer
      • Oviedo, Spania, 33011
        • Hospital Universitario Central de Asturias
      • Palma de Mallorca, Spania, 07198
        • Hosp. Son Llatzer
      • Pontevedra, Spania, 36071
        • Hosp. Montecelo
      • Pozuelo de Alarcón, Spania, 28223
        • Hosp. Quiron Madrid Pozuelo
      • Valencia, Spania, 46026
        • Hospital Universitari i Politecnic La Fe
      • Aberdeen, Storbritannia, AB25 2ZN
        • Aberdeen Royal Infirmary
      • Birmingham, Storbritannia, B15 2GW
        • University Hospitals Birmingham NHS Foundation Trust
      • Colchester, Storbritannia, CO4 5JL
        • Colchester Hospital University NHS
      • Liverpool, Storbritannia, L7 8YA
        • The Clatterbridge Cancer Centre
      • London, Storbritannia, SW17 0QT
        • St Georges Hospital
      • London, Storbritannia, SW10 9NH
        • Chelsea And Westminster Hospital
      • Middlesbrough, Storbritannia, Ts4 3Bw
        • James Cook University Hospital
      • Norwich, Storbritannia, NR4 7UY
        • Norfolk and Norwich University Hospital
      • Staffordshire, Storbritannia, ST4 6QG
        • Royal Stoke University Hospital
      • Falun, Sverige, 791 82
        • Falu Lasarett Medicinkliniken Falun
      • Helsingborg, Sverige, 25287
        • Helsingborgs lasarett
      • Uppsala, Sverige, 751 85
        • Akademiska Sjukhuset
      • Brno, Tsjekkia, 625 00
        • Fakultni nemocnice Brno
      • Olomouc, Tsjekkia, 779 00
        • Fakultni nemocnice Olomouc
      • Ostrava - Poruba, Tsjekkia, 708 52
        • Fakultni Nemocnice Ostrava
      • Prague, Tsjekkia, 128 08
        • Vseobecna fakultni nemocnice v Praze
      • Ankara, Tyrkia (Türkiye), 06200
        • Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
      • Ankara, Tyrkia (Türkiye), 06680
        • Liv Hospital Ankara
      • Ankara, Tyrkia (Türkiye), 06620
        • Ankara University Medical Faculty
      • Ankara, Tyrkia (Türkiye), 06010
        • Ankara Gulhane Training and Research Hospital
      • Antalya, Tyrkia (Türkiye), 07100
        • Antalya Training And Research Hospital
      • Denizli, Tyrkia (Türkiye), 20070
        • Pamukkale University Medical Faculty
      • Istanbul, Tyrkia (Türkiye), 34214
        • Medipol Mega Universite Hastanesi
      • Samsun, Tyrkia (Türkiye), 55280
        • Ondokuz Mayis University
      • Cottbus, Tyskland, 03048
        • Medizinische Universitat Lausitz Carl Thiem
      • Dresden, Tyskland, 01307
        • Universitatsklinikum Carl Gustav Carus Dresden
      • Greifswald, Tyskland, 17475
        • Universitätsmedizin Greifswald
      • Hamburg, Tyskland, 22763
        • Asklepios Klinik Altona
      • Heidelberg, Tyskland, 69120
        • Universitaetsklinikum Heidelberg
      • Marburg, Tyskland, 35043
        • Universitaetsklinikum Giessen und Marburg GmbH
      • Tübingen, Tyskland, 72076
        • Universitatsklinikum Tubingen
      • Ulm, Tyskland, 89070
        • Universitatsklinikum Ulm
      • Zwickau, Tyskland, 08060
        • Heinrich-Braun-Klinikum gGmbH
      • Salzburg, Østerrike, 5020
        • LKH - Universitätsklinikum der PMU Salzburg
      • Vienna, Østerrike, A-1090
        • Medical University Vienna MUV

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Documented diagnosis of multiple myeloma as defined by the criteria below: (a)Multiple myeloma diagnosis according to International Myeloma Working Group (IMWG) diagnostic criteria (b) Measurable disease at screening as defined by any of the following: (1) Serum M-protein level greater than or equal to (>=)0.5 grams per deciliter (g/dL) (central laboratory); or (2) Urine M-protein level >=200 milligrams (mg)/24 hours (central laboratory); or (3) Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio
  • Received 1 to 3 prior lines of antimyeloma therapy including a minimum of 2 consecutive cycles of an anti- cluster of differentiation 38 (CD38) monoclonal antibody at the approved dosing regimen in any prior line and 2 consecutive cycles of lenalidomide in any prior line
  • Documented evidence of progressive disease or failure to achieve a response to last line of therapy based on investigator's determination of response by International myeloma working group (IMWG) criteria
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • A female participant must agree not to be pregnant, breast-feeding, or plan to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment
  • Must be willing and able to adhere to the lifestyle restrictions specified in this protocol

Exclusion Criteria:

  • Received any prior B cell maturation antigen (BCMA)-directed therapy
  • A participant is not eligible to receive PVd as control therapy if any of the following are present: (1) Received prior pomalidomide therapy, (2) Does not meet criteria for bortezomib retreatment (3) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide or bortezomib, (4) Grade 1 peripheral neuropathy with pain or Grade greater than or equal to (>=) 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, (5) Received a strong cytochrome P (CYP) 3A4 inducer within 5 half-lives prior to randomization; A participant is not eligible to receive Kd as control therapy if any of the following are present:(1) Received prior carfilzomib therapy, (2) Uncontrolled hypertension, defined as an average systolic blood pressure greater than (>)159 millimeters of mercury (mmHg) or diastolic blood pressure >99 mmHg despite optimal treatment (3) Grade 2 peripheral neuropathy with pain or Grade >=3 peripheral neuropathy as defined by NCI-CTCAE Version 5.0, (4) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to carfilzomib (intolerance defined as prior therapy discontinued due to any adverse event [AE] related to carfilzomib)
  • Received a maximum cumulative dose of corticosteroids of >=140 mg of prednisone or equivalent within 14 days prior to randomization
  • Received a live, attenuated vaccine within 4 weeks before randomization
  • Central nervous system (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma
  • Plasma cell leukemia at the time of screening, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein (POEMS) syndrome and skin changes, or primary amyloid light chain amyloidosis

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Teclistamab

Participants will receive teclistamab monotherapy in Part 1 and an alternative dosing regimen of teclistamab in Part 2. Participants who are still receiving the treatment and benefiting from it may enter the long-term extension (LTE) and drug access (DA)-LTE Phases to continue their current treatment until end of the study.

Teclistamab will be administered subcutaneously.

Andre navn:
  • JNJ-64007957
Eksperimentell: Pomalidomide, Bortezomib and Dexamethasone (PVd) or Carfilzomib and Dexamethasone (Kd)

Participants will receive either PVd or Kd based on principal investigator's choice during Part 1 of the study. Participants who are still receiving the treatment and benefiting from it may enter the LTE and DA-LTE Phases to continue their current treatment until end of the study.

Pomalidomide will be administered orally.

Carfilzomib will be administered intravenously.

Bortezomib will be administered subcutaneously.

Dexamethasone will be administered orally in PVd and intravenously or orally in Kd.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Part 1: Progression-free Survival (PFS)
Tidsramme: Up to 9 years

PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International myeloma working group (IMWG) 2016 response criteria, or death due to any cause, whichever occurs first.

Up to 9 years
Part 2: Number of Participants Reporting Cytokine Release Syndrome (CRS) Cases by Severity
Tidsramme: Up to 9 years

Severity for CRS will be graded as follows: Grade 1: Fever (Temperature greater than or equal to [>=] 38°C); Grade 2: Fever (Temperature >=38°C) with either: hypotension and/or hypoxia requiring low-flow nasal cannula or blow-by; Grade 3: Fever (Temperature >=38°C) with either: hypotension and/or hypoxia requiring high-flow nasal cannula, facemask, nonrebreather mask, or Venturi mask; Grade 4: Fever (Temperature >=38°C) with either: hypotension requiring multiple vasopressors (excluding vasopressin), and/or hypoxia requiring positive pressure and Grade 5: Death.

Up to 9 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Part 1 and 2: Overall Response (Partial Response [PR] or Better)
Tidsramme: Up to 9 years

Overall response (PR or better) is defined as participants who have a PR or better prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.

Up to 9 years
Part 1 and 2: Very Good Partial Response (VGPR) or Better Response
Tidsramme: Up to 9 years

VGPR or better (Stringent Complete Response [sCR]+Complete Response [CR]+VGPR) is defined as participants who achieve a VGPR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.

Up to 9 years
Part 1 and 2: Complete Response (CR) or Better Response
Tidsramme: Up to 9 years

CR or better response is defined as participants who achieve a CR or better response prior to subsequent antimyeloma therapy in accordance with the IMWG 2016 criteria.

Up to 9 years
Part 1: Duration of Response (DOR)
Tidsramme: Up to 9 years

DOR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG 2016 response criteria or death due to any cause, whichever occurs first.

Up to 9 years
Part 1: Time to Next Treatment (TTNT)
Tidsramme: Up to 9 years

TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment.

Up to 9 years
Part 1: Progression-free Survival on Next-line Therapy (PFS2)
Tidsramme: Up to 9 years

PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first.

Up to 9 years
Part 1: Overall Survival (OS)
Tidsramme: Up to 9 years

OS is defined as the time from the date of randomization to the date of the participant's death due to any cause.

Up to 9 years
Part 1 and 2: Number of Participants with Adverse Events (AEs) by Severity
Tidsramme: Up to 9 years

Number of participants with AEs by Severity will be reported.

Up to 9 years
Part 1 and 2: Number of Participants with Serious Adverse Events (SAEs) by Severity
Tidsramme: Up to 9 years

Number of participants with SAEs by Severity will be reported.

Up to 9 years
Part 1 and 2: Number of Participants with Abnormal Laboratory Results
Tidsramme: Up to 9 years

Number of participants with abnormal laboratory results (such as hematology and chemistry) will be reported.

Up to 9 years
Part 1 and 2: Serum Concentrations of Teclistamab
Tidsramme: Up to 9 years

Serum concentrations of teclistamab will be reported.

Up to 9 years
Part 1 and 2: Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab
Tidsramme: Up to 9 years

Number of participants with ADAs to teclistamab will be reported.

Up to 9 years
Part 1: Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)
Tidsramme: Baseline up to 9 years

Change from baseline in symptoms, functioning, and overall HRQoL assessed by EORTC QLQ-C30 score version 3 will be reported. The EORTC- QLQ-C30 Version 3 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

Baseline up to 9 years
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score
Tidsramme: Baseline up to 9 years

Change from baseline in symptoms, functioning, and overall HRQoL assessed by MySIm-Q will be reported. The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale.

Baseline up to 9 years
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tidsramme: Baseline up to 9 years

Change from baseline in symptoms, functioning, and overall HRQoL assessed by PRO-CTCAE will be reported. The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact.

Baseline up to 9 years
Part 1: Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
Tidsramme: Baseline up to 9 years

Change from baseline in symptoms, functioning, and overall HRQoL assessed by EQ-5D-5L will be reported. The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).

Baseline up to 9 years
Part 1: Time to Worsening in Symptoms, Functioning, and Overall HRQoL
Tidsramme: Up to 9 years

Time to worsening in symptoms, functioning, and overall HRQoL will be measured as the interval from the date of randomization to the start date of meaningful change.

Up to 9 years
Part 1: PFS in Participants in High-risk Molecular Features
Tidsramme: Up to 9 years

PFS in participants in high-risk molecular features will be reported. PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the IMWG 2016 response criteria, or death due to any cause, whichever occurs first.

Up to 9 years
Part 1: Depth of Response in Participants in High-risk Molecular Features
Tidsramme: Up to 9 years

Depth of response in participants in high-risk molecular features will be reported.

Up to 9 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

29. mars 2023

Primær fullføring (Faktiske)

13. oktober 2025

Studiet fullført (Antatt)

31. august 2031

Datoer for studieregistrering

Først innsendt

5. oktober 2022

Først innsendt som oppfylte QC-kriteriene

5. oktober 2022

Først lagt ut (Faktiske)

7. oktober 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere